This site is intended for Great Britain healthcare professionals only 

Visit Pfizer Medical site



Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub



AboutAboutHow Cibinqo worksIntroducing CibinqoMOA OverviewPatient ProfilesPatient Profiles OverviewPatient Profile 1Patient Profile 2Patient Profile 3Patient Profile 4EfficacyEfficacyClinical EfficacyStudy OverviewJADE COMPAREJADE MONOJADE REGIMENJADE TEENJADE EXTENDSafety
Safety Guidance
DosingDosingDosingOral once-daily dosingPractical ConsiderationsSupport & ResourcesSupport & ResourcesHCP ResourcesMedicine Evidence InformationPatient ResourcesVideos

Information on how to access Cibinqo® (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

Patient profilesPatient profile 1

Unemployed male with increasingly uncontrolled itching leading to sleep deprivation, weight gain and low self-esteem.

View profileLoading
Patient profile 2

Middle-aged mother with uncontrolled, severe eczematous lesions, resulting in self-consciousness and anxiety.

View profileLoading
Patient profile 3

Young professional female with persistent, uncontrolled itching and lesions that are impacting her work.

View profileLoading
Patient profile 4

Teenage competitive swimmer suffering with regular disease flares and itching.

View profileLoading
Explore moreDosing

Learn more about flexible dosing in patients on Cibinqo.

Discover oral once-daily dosingLoading
Practical considerations

Learn more about monitoring patients on Cibinqo.

View requirementsLoading

These patient profiles are fictional and have been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional.

Prescribing information:​​​​​​​
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.

PP-CIB-GBR-0055. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from Patients treated with Cibinqo should be given the Patient Card.

Adverse events should be reported. Reporting forms and information can be found at or search 

for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

Copyright © 2021 Pfizer Limited. All rights reserved.

VAT registration number GB201048427

PP-PFE-GBR-3849. November 2021

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?

You are now leaving PfizerPro
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes No
You are now leaving PfizerPro
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021